Immune checkpoint blockade (ICB) induces a remarkable and durable response in a subset
of cancer patients. However, most patients exhibit either primary or acquired resistance to …

Many mechanisms underlying an effective immunotherapy-induced antitumour response are
transient and critically time dependent. This is equally true for several immunological events …

The lack of comprehensive diagnostics and consensus analytical models for evaluating the
status of a patient's immune system has hindered a wider adoption of immunoprofiling for …

Unsatisfied tumor accumulation of chemotherapeutic drugs and a complicated
immunosuppressive microenvironment diminish the immune response rate and the …

Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the
treatment, and distinguishing responders from non-responders is a major challenge. Many …

Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown
promising efficacy in melanoma. However, the underlying mechanism in humans remains …

Immune checkpoint inhibitors (ICIs) have dramatically transformed the treatment landscape
for various malignancies, achieving notable clinical outcomes across a wide range of …

Abstract Treatment with immune checkpoint inhibitors, widely known as immune checkpoint
blockade therapy (ICBT), is now the fourth pillar in cancer treatment, offering the chance of …

Abstract β2-microglobulin (B2M) is a critical component of the MHC class I molecule and is
required to present tumor antigens to T cells. Its loss results in acquired resistance to …